Year: 2023

Further to an announcement dated September 27th, Iceland Seafood International hereby convene a bondholders meeting for bonds in the series ICESEA 25 06, ISIN: IS0000033199, on Wednesday October 25th 2023 at 10am.  The meeting will be held at the premises of Kvika Banki, Katrínartúni 2, 105 Reykjavík.  Voting rights will be in accordance with bondholders list at end of October 24th 2023.  The only agenda of the meeting is to decide on a consent in relation to condition 9.3 of the terms and condition for the Bonds, since the sale of Iceland Seafood UK Ltd means that assets representing more than 5% of total group turnover are being sold.  To compensate bondholders for granting this consent, the issuer will amend the interest rates of the bond to reflect changes in market conditions since the bond was issued.  Further information in relation...

October 18th 2023        Photocat Enters Transformative 3-Years Procurement Agreement with Spanish Pavement Producer Prefabricados de la Jara (Province of Cuenca) Roskilde, Denmark. October 18, 2023 – Photocat, a global leader in sustainable photocatalytic solutions, is thrilled to announce a groundbreaking partnership with Prefabricados de la Jara, a pioneering Spanish pavement producer. This collaboration marks the inception of a transformative 3-years procurement agreement, wherein Photocat will supply its cutting-edge photocatalytic technology to enhance the environmental performance of Prefabricados de la Jara’s pavement stone solutions – under their brand name ‘CLEANNOX’. Key Partnership Highlights:Three-Years Commitment: Under this agreement, Photocat and Prefabricados de la Jara are committed to a three-years partnership,...

  TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The New England Journal of MedicineTZIELD met the study’s primary endpoint, significantly slowing the decline of C-peptide levels, compared to placebo Numerical trends favoring TZIELD were seen in key secondary endpoints, whilst statistical significance was not achieved PROTECT builds on the existing body of evidence on TZIELD’s potential to slow the progression of type 1 diabetes TZIELD fits at the intersection of Sanofi’s growth in immune-mediated diseases and disease modifying therapies, and the company’s expertise in diabetesParis, October 18, 2023. New data from TZIELD’s (teplizumab-mzwv) PROTECT Phase 3 trial were presented today at the...

Sanoma Corporation, Press Release, 18 October 2023 at 11:00 EET Sanoma has signed a new EUR 100 million term loan to repay the EUR 200 million bond in March 2024 Sanoma Corporation has signed a bilateral EUR 100 million term loan facility agreement with OP Corporate Bank. Maturity of the new term loan is twelve months from the drawdown plus an extension option of ten months at the discretion of Sanoma. Sanoma will withdraw the loan in March 2024 and use the funds, together with its other existing funding facilities to repay the EUR 200 million bond, expiring on 18 March 2024. In addition, the maturity of Sanoma’s EUR 300 million syndicated Revolving Credit Facility (RCF) has been extended by one year to November 2026. The RCF is provided by a group of ten relationship banks and is currently fully unused. “In the current interest rate environment,...

Valoe Corporation        Stock Exchange Release 18 October 2023 at 11.18 Finnish time The notification of major holdings disclosed by Valoe on 18 October 2023 at 9.20 a.m. incorrectly stated that Nordic Environment Finance Corporation’s shareholding in Valoe shares has crossed the threshold of 5% of all the shares in Valoe due to disposal of shares in Valoe. However, the threshold is crossed due to a change in the total number of shares in Valoe. Below is a corrected Disclosure under Chapter 9, Section 10 of the Securities Market Act. Disclosure under Chapter 9, Section 10 of the Securities Market Act. Valoe Corporation has received the following announcement regarding disclosure under chapter 9, section 10 of the Securities Market Act. Valoe has received an announcement from Nordic Environment Finance Corporation according to which its...

Neonatal sepsis is a leading cause of death for newborns Testing IL-6 can indicate a neonatal sepsis infection earlier than other biomarkers Earlier diagnosis of neonatal sepsis can lead to improved outcomes and a reduction of long-term complications from sepsisBasel, 18 October 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Elecsys IL-6 immunoassay has become the first IL-6 test to have a certified claim for use in diagnosis of neonatal sepsis, in countries accepting the CE Mark.* Elecsys IL-6 aids physicians in combating the impact of neonatal sepsis by facilitating an early diagnosis. Early and improved diagnosis can contribute to appropriate use of antibiotics, as well as potentially decreasing mortality rates and mitigating long-term consequences of sepsis. “Sepsis is one of the leading causes of death...

These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC) With about one in two people with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy,1 more effective treatment options are urgently needed to provide the best chance for cure2 Data are being presented as a late-breaking oral during the ESMO 2023 Presidential SymposiumBasel, 18 October 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the primary analysis of the Phase III ALINA study demonstrating a statistically significant and clinically meaningful improvement in disease-free survival (DFS; primary endpoint). The study results showed that Alecensa® (alectinib) reduces the risk of disease recurrence...

WISeKey and Aesopower team up to introduce secure street lighting controller to smart city market GENEVA – October 18, 2023: WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leader in cybersecurity, digital identity, and Internet of Things (IoT) solutions operating as a holding company, today announced that its Semiconductors & PKI subsidiary SEALSQ Corp. (“SEALSQ”) (NASDAQ: LAES) was selected by Aesopower, a leading wireless connectivity solution provider, to supply its secure element ValutIC408 into their street lighting controller with cryptographic technology that can safeguard the device against the most sophisticated cyberattacks.  The VaultIC408 is a tamper resistant secure microcontroller with embedded firmware designed for strong device authentication and secure communication. The targeted markets...